Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover safety study of Tafinlar and/or Mekinist in BRAF V600 mutation-positive metastatic melanoma
2017-001987-39Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dabrafenib + trametinib and trametinib in melanoma (3 arms), sponsored by Novartis. Primary endpoint: Frequency and severity of AEs/SAEs. Started Oct 2017; status: active.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-001987-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001987-39.